RxDoctor Payments Data

David Menchell, MD

Allergy/ Immunology · Fresh Meadows, NYNPI 1942224415

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.3% of the total across 101 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 23.5% — the pattern of someone who eats at a lot of different presentations.

$2,625in general payments, 2019–2025

Across 101 payments — averaging $25.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$618
  • Sanofi$484
  • GSK$370
  • Optinose US, Inc.$215
  • Amgen$189
  • AstraZeneca$165
  • plus $584 from 9 others

What the payments were for

  • Food & beverage$2,52796%
  • Education$984%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few allergy/ immunology providers in New Yorkto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$254,244
Medicare patients
143
Services billed
6,671

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammakedImmune Globul G/Gly/Iga Avg 4613$76,934
Breo ElliptaFluticasone/Vilanterol28$23,924
Combivent RespimatIpratropium/Albuterol Sulfate18$8,655
Advair DiskusFluticasone Propion/Salmeterol14$6,406
SymbicortBudesonide/Formoterol Fumarate11$3,511
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$2,728
Cromolyn Sodium14$2,326
Albuterol Sulfate HfaAlbuterol Sulfate55$1,355
Halobetasol Propionate12$1,254
Azelastine Hcl37$891
Fluticasone Propionate45$618
Levocetirizine Dihydrochloride22$371
Triamcinolone Acetonide11$164
Montelukast Sodium15$159
Prednisone19$82

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta$370$23,92428 claims
AstraZenecaSymbicort$165$3,51111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy/ immunology providers in New Yorkon file to place this against a meaningful peer group, so we don't.

Other allergy/ immunology in Fresh Meadows

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →